Fresenius Kabi AG Introduces Cisatracurium Besylate Injection, A New Specialty Injectable Product, In Three Presentations

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced Cisatracurium Besylate Injection in the U.S. The drug was approved by the U.S. Food and Drug Administration earlier this year.

“With the introduction of Cisatracurium, Fresenius Kabi delivers clinicians another choice in neuromuscular blockers while fostering our commitment to provide customers access to one of the most comprehensive anesthesia portfolios in the U.S.”

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

Cisatracurium Besylate, the generic equivalent of NIMBEX^®, is an intermediate-onset and intermediate-duration neuromuscular blocker for inpatient and outpatient use as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the intensive care unit.

“With the introduction of Cisatracurium, Fresenius Kabi delivers clinicians another choice in neuromuscular blockers while fostering our commitment to provide customers access to one of the most comprehensive anesthesia portfolios in the U.S.,” said John Ducker, president and CEO of Fresenius Kabi USA.

Fresenius Kabi Cisatracurium is available in three presentations: a 10mg per 5mL single use vial, a 20 mg per 10mL multiple dose vial and a 200 mg per 20mL single use vial.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.